Praxis Precision Medicines, Inc.

Praxis Precision Medicines is not giving up on ulixacaltamide in essential tremor (ET) after the independent data monitoring committee (IDMC) for the Phase III Essential3 program said one of the progr

Focused on treating rare forms of epilepsy, Praxis Precision Medicines, Inc. reported Phase II proof-of-concept data on 3 September that it believes will position relutrigine (PRAX-562), a selective

US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w

At least five biopharma companies have filed paperwork with the US Securities and Exchange Commission (SEC) since the start of 2024 to signal their intention to go public this year, entering what stil